Enfermedad nodular tiroidea

  1. E. Anda 1
  2. J. Pineda 1
  3. M. Toni 2
  4. J.C. Galofré 3
  1. 1 Complejo Hospitalario de Navarra. Pamplona. Navarra. España
  2. 2 Instituto de Investigación Sanitaria de Navarra (IdiSNA). Pamplona. Navarra. España
  3. 3 Universidad de Navarra. Pamplona. Navarra. España
Show affiliations +
Journal:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Year of publication: 2016

Issue Title: Enfermedades endocrinológicas y metabólicas (I) Patología del tiroides

Series: 12

Issue: 13

Pages: 713-721

Type: Article

DOI: 10.1016/J.MED.2016.06.001 DIALNET GOOGLE SCHOLAR

More publications in: Medicine: Programa de Formación Médica Continuada Acreditado

Sustainable development goals

Abstract

Introduction Thyroid nodules are very frequent in our clinical practice and most of them are benign (85%). History and clinical examination Thyroid nodules are usually asymptomatic. The clinical importance of nodular thyroid disease is related to the possibility of malignancy. Their study should always include thyroid function test and the evaluation of compressive or structural symptoms. Evaluation In all patients with a thyroid nodule, a complete history and physical examination, a serum TSH measurement and a cervical ultrasonography should be performed. Thyroid ultrasonography should evaluate the location and sonographic characteristics of all nodules. The nodule size and the pattern of sonographic features confer the risk of malignancy and aid decision-making process about whether fine needle aspiration (FNA) is indicated. The FNA technique is the most accurate method for evaluating thyroid nodules. Some molecular markers may be considered to improve diagnostic accuracy. Treatment According to the cytology results the nodules will be considered for surgical excision or for conservative follow-up.

Bibliographic References

  • Gharib H, Papini E, Paschke R, Duick KS, Valcavi R, Hegedüs L, et al. American Association of Clinical Endocrinologist, Associ-azione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and man-agement of thyroid nodules. Endocr Pract. 2010;16Suppl1:1-43.
  • Guth S, Theune U, Aberle J, Galach A, Bamberger CM. Very high preva-lence of thyroid nodules detected by high frequency (13 MHz) ultra-sound examination. Eur J Clin Invest. 2009;39:226-31.
  • Mortensen JK, Woolner LB, Bennett WA. Gross and microscopic fin-dings in clinically normal thyroid glands. J Clin Endocrinol Metab. 1995;15:1270-80.
  • Tan GH, Gharib H, Reading CC. Solitary thyroid nodule. Comparison between palpation and ultrasonography. Arch Intern Med. 1995;155:2418-23.
  • Knobel M. Etiopathology, clinical features, and treatment of diffuse and multinodular nontoxic goiters. J Endocrinol Invest. 2016;39(4):357-73.
  • Bayer Y, Neumann S, Meyer B, Rüschendorf F, Reske A, Brix T, et al. Ge-nome-wide linkage analysis reveals evidence for four new susceptibility foci for familial euthyroid goiter. J Clin Endocr Metab. 2004;89:4044-53.
  • Robenshtok E, Tzvetov G, Grozinsky-Glasberg S, Shraga-Slutzky I, Weinstein R, Lazar L, et al. Clinical characteristics and outcome of fami-lial nonmedullary thyroid cancer: a retrospective controlled study. Thyroid. 2011;21:43-8.
  • Jin J, McHenry CR. Thyroid incidentaloma. Best Pract Res Clin Endo-crinol Metabol. 2012;26:83-96.
  • Soelberg KK, Bonnema SJ, Brix TH, Hegedus L. Risk of malignancy in thyroid incidentalomas detected by 18F-Fluorodeoxyglucose Positron Emission Tomography: a systematic review. Thyroid. 2012;22:918-25.
  • Frates MC, Benson CB, Doubilet PM, Kunreuther E, Contreras M, Ci-bas ES, et al. Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography. J Clin Endocrinol Metab. 2006;91:3411-7.
  • Brito JP, Yarur AJ, Prokop LJ, McIver B, Murad MH, Montori VM. Pre-valence of thyroid cancer in multinodular goiter versus single nodule: a systematic review and meta-analysis. Thyroid. 2013;23:449-55.
  • Alexander K, Hurwitz S, Heering B, Benson CB, Frates MC, Doubilet PM, et al. Natural history of benign solid and cystic thyroid nodules. Ann Intern Med. 2003;138:315-8.
  • Durante C, Costante G, Lucisano G, Bruno R, Meringolo D, Paciaroni A, et al. The natural history of benign thyroid nodules. JAMA. 2015;313: 926-35.
  • Ajmal S, Rapoport S, Ramírez H, Mazzaglia PJ. The natural history of the benign thyroid nodule: What is the appropriate follow-up strategy? J Am Coll Surg. 2015;220:987-92.
  • Vivanco, M, Dalle JH, Alberti C, Lescoeur B, Yakouben K, Carel JC, et al. Malignant and benign thyroid nodules after total body irradiation pre-ceding hematopoietic cell transplantation during childhood. Eur J Endo-crinol. 2012;167:225-33.
  • Tronko MD, Howe GR, Bogdanova TI, Bouville AC, Epstein OV, Brill AB, et al. A cohort study of thyroid cancer and other thyroid diseases after the Chernobyl accident: thyroid cancer in Ukraine detected during first screening. J Natl Cancer Inst. 2006;13:897-903.
  • Rowland KJ, Moley JF. Hereditary thyroid cancer syndromes and genetic testing. J Surg Oncol. 2015;111:51-60.
  • Rutter M, Jha P, Schultz KA, Sheil A, Harris A, Bauer, et al. DICER1 mutations and differentiated thyroid carcinoma: evidence of a direct as-sociation. J Clin Endocrinol Metab. 2016;101:1-5.
  • Son EJ, Nosé V. Familial follicular cell-derived thyroid carcinoma. Front Endocrinol (Lausanne). 2012;3:61.
  • Boelaert K, Horacek J, Holder RL, Watkinson JC, Sheppard MC, Franklyn JA. Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. J Clin Endocrinol Metab. 2006;91:4295-301.
  • Haymart MR, Repplinger KJ, Leverson GE, Elson DF, Sippel RS, Jaume JC, et al. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab. 2008;93:809-14.
  • Cooper DS, Doherty GM, Haugen BT, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167-214.
  • Horvath E, Majlis S, Rossi R, Franco C, Niedmann JP, Castro A, et al. An ultrasonogram reporting system for thyroid nodules stratifying cancer risk for clinical management. J Clin Endocrinol Metab. 2009;94:1748-51.
  • Haugen BR, Alexander EK, Bible KC Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association manage-ment guidelines for adult patients with thyroid nodules and diffe-rentiated thyroid cancer. Thyroid. 2016;26:1-133.
  • Kovács G, Gonda G, Vadász G, Ludmány E, Uhrin K, Görömbey Z, et al. Epidemiology of thyroid microcarcinoma found in autopsy series con-ducted in areas of different iodine intake. Thyroid. 2005;2:152-7.
  • Ito Y, Miyauchi A, Inoue H. An observational trial for papillary thyroid microcarcinoma in Japanese patients. Worl J Surg. 2010;34:28-35.
  • Cibas ES, Ali SZ. The Bethesda system for reporting thyroid cytopatho-logy. Am J Clin Pathol. 2009;132:658-65.
  • Bongiovanni M, Spitale A, Faquin WC, Mazzucchelli L, Baloch ZW. The Bethesda System for reporting thyroid cytopathology: a meta-analysis. Acta Cytologica. 2012;56:333-9.
  • Nikiforova MN, Wald AI, Roy S, Durso MB, Nikiforov YE. Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J Clin Endocrinol Metab. 2013;98:1852-60.
  • Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J, et al. Preoperative diagnosis of benign thyroid nodules with indetermi-nate cytology. N Engl J Med. 2012;367:705-15.
  • Yoo WS, Choi HS, Cho SW, Moon JH, Kim KW, Park HJ, et al. The role of ultrasound findings in the management of thyroid nodules with atypia or follicular lesions of undetermined significance. Clin Endocrinol. 2014; 80:735-42.
  • Kwak JY, Koo H, Youk JH, Kim MJ, Moon HJ, Son EJ, et al. Value of US correlation of a thyroid nodule with initially benign cytologic results. Ra-diology. 2010;254:292-300.
  • Nou E, Kwsong N, Alexanter LD, Cibas ES, Marqusee E, Alexander EK. Determination of the optimal time interval for repeat evaluation after a benign thyroid nodule aspiration. J Clin Endocrinol Metab. 2014;99: 510-16.
  • Wharry LI, McCoy KL, Stang MT, Armstrong MJ, LeBeau SO, Tublin ME, et al. Thyroid nodules (≥4 cm): can ultrasound and cytology reliable exclude cancer? World J Surg. 2014;38:614-21.
  • Albuja-Cruz MB, Goldfarb M, Gondek SS, Allan BJ, Lew JL. Reliability of fine-needle aspiration for thyroid nodules greater than or equal to 4 cm. J Surg Res. 2013;181:6-10.
  • Sdano MT, Falciglia M, Welge JA, Steward DL. Efficacy of thyroid hor-mone suppression for benign thyroid nodules: meta-analysis of randomi-zed trials. Otolaryngol Head Neck Surg. 2005;133:391.
  • Suh CH, Baek JH, Ha EJ, Choi YJ, Lee JH, Kim JK, et al. Ethanol abla-tion of predominantly cystic thyroid nodules: evaluation of recurrence rate and factors related to recurrence. Clin Radiol. 2015;70:42-7.
  • Jeong WK, Baek JH, Rhim H, Kim YS, Kwak MS, Jeong HJ, et al. Radio-frequency ablation of benign thyroid nodules: safety and imaging follow-up in 236 patients. Eur Radiol. 2008;18:1244-39.
Data source: Dialnet